Navigation Links
Auxogyn Announces Strategic Partnership with Valencia Infertility Institute (IVI)

MENLO PARK, Calif., July 25, 2013 /PRNewswire/ -- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced it has entered into a strategic partnership with the Valencia Infertility Institute (IVI), a global leader in reproductive medicine with 23 clinics throughout the world.

Under the terms of this multi-year agreement, Auxogyn will install its Early Embryo Viability Assessment (Eeva™) systems at IVI clinics to support two Auxogyn-led research initiatives: the Eeva Pregnancy Investigational Clinical (EPIC) Study and an aneuploidy research program. IVI will use the Eeva systems to treat at least 200 patients participating in the EPIC Study in Europe, which will evaluate the impact on clinical pregnancy rates of improved embryo selection with the Eeva Test. This partnership will also support Auxogyn's current aneuploidy (an abnormal number of chromosomes) research programs, which – by leveraging the Eeva system – could lead to the development of non-invasive, automated methods for aneuploidy screening.

"Auxogyn is very pleased to collaborate with IVI, which has one of the world's largest networks of IVF clinics and a proven track record of promoting clinical and scientific progress through cutting-edge research," stated Lissa Goldenstein, President and CEO of Auxogyn. "Through this partnership, we're accelerating our growth in Europe and advancing our mission of improving outcomes for patients undergoing IVF."

Installation of the Eeva systems at IVI clinics in Spain is scheduled to occur in August 2013. These will be the first clinics in Spain to offer this innovative technology to eligible patients who enroll in the Auxogyn research studies.

"IVI prides itself on leveraging new approaches to offer patients the latest treatment options to achieve the best results," stated Dr. Antonio Pellicer, founder of IVI. "We look forward to partnering with Auxogyn on important research that offers new hope to our patients and advances the reproductive medicine field."

About Auxogyn
Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers consistent, objective information regarding embryo viability that IVF clinicians and patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information visit and follow us on Twitter @Auxogyn.

About the Early Embryo Viability Assessment (Eeva™) Test
The Eeva Test provides IVF clinicians with predictive information about the embryo's development potential to help improve embryo selection. Eeva's proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters conceived by researchers at Stanford University in the US. With results from the Eeva Test, IVF teams now have predictive and objective information to combine morphological assessment to help improve the embryo selection decision. The Eeva Test was validated in a prospective, multi-centre, 54-patient clinical trial with 755 embryos. Embryologists using Eeva results were significantly able to improve their ability to identify non-viable embryos relative to traditional methods alone. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were initially presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.

Eeva is currently CE Marked and available for use in the EU and is pending FDA clearance in the United States. For a full list of clinics in the EU offering the Eeva Test please visit or follow us on Twitter @EevaIVF.

About IVI Spain
IVI was created in 1990 as the first medical institution in Spain to specialise entirely in Human Reproduction. Since then, it has helped more than 55,000 babies to be born thanks to its use of the newest assisted reproduction methods. At IVI clinics we carry out all of the assisted reproduction techniques that are currently available, and it is one of the European centres with the best pregnancy rates; in fact, 9 out of 10 couples who come to IVI because of fertility problems manage to achieve their goal. IVI currently has 23 clinics in 7 countries, and is a leader in reproductive medicine. For more information visit

SOURCE Auxogyn, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:12/1/2015)... , Dec. 01, 2015 ... the addition of the "Medium Molecular ... Sealants, Lubricants, and Other Applications - Global ... Forecast, 2015 - 2023" report to ... has announced the addition of the ...
(Date:12/1/2015)... 2015 WellStar Health System has signed a ... -based Tenet Healthcare,s five metro Atlanta ... strategic move following the conclusion of the due diligence ... models and patient safety programs that have resulted in ... communities. --> --> ...
(Date:12/1/2015)... , Dec. 01, 2015 ... addition of the "Spinal Muscular Atrophy ... and Forecast 2015 - 2023" report ... ) has announced the addition of the ... Assessment, Size, Growth, Trends, and Forecast 2015 ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... The North American Meat Institute today unveiled ... poultry play in a healthy, balanced diet. , includes a section about ... their “meat IQ,” a section offering straight talk on controversies, information on buying ...
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , a vertically integrated ... that allows for easier packing and organizing of items into one big, portable jar. ... Scott Cooper, CEO and Creative Director of World Patent Marketing and Desa Industries ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, a town of about ... Internet through a partnership this year with Aeneas Internet and Telephone. , With ... destination for entrepreneurs who want to build a business. Whether startups or long ...
(Date:12/1/2015)... , ... December 02, 2015 , ... ... “ Gastrointestinal events and association with initiation of treatment for osteoporosis ”. , ... use of pharmacological treatment in patients diagnosed with osteoporosis. Based on a large ...
(Date:12/1/2015)... ... 2015 , ... Royal River Natural Foods — a locally-owned, independent natural health ... took the nutritional supplement creatine, along with resistance training for a year, had more ... , The report is part of the December 2015 issue of Natural Insights for ...
Breaking Medicine News(10 mins):